GT Biopharma GTBP
NASDAQ GTBP
$5.41 -1.90 (-25.99%)
At close: Oct 21, 2026 · 4:00 PM EDT

GT Biopharma (GTBP) EBITDA Margin (2015)

Updated

GT Biopharma (GTBP) posted EBITDA Margin of -33055.56% for FY2015, down 29163.75 percentage points from -3891.80% in FY2014.

Analysis

GT Biopharma (GTBP) EBITDA Margin (2015) Analysis & Trends

  • Business Quant data shows GTBP's EBITDA Margin at -3891.80% in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 53.49%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 35.95%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 49.01%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 6.02%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 33.11%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 46.01%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -124.26%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 39.16%
10 GT Biopharma 6.53 Mn -16.96 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2015 -7,160.00%
Mar 31, 2015 72,442.86%
API Access

GT Biopharma EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=GTBP&period=max&api_key=YOUR_API_KEY